GNMSF — GENMAB A/S
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1434265 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,187,000,000 | 1,099,000,000 | 441,000,000 | 342,000,000 | 12,936,000,000 | 1,860,000,000 | 6,603,000,000 |
| Jun 2026 | 1,155,000,000 | 1,071,000,000 | 407,000,000 | 303,000,000 | 12,515,000,000 | 1,503,000,000 | 6,558,000,000 |
| Mar 2026 | 896,000,000 | 831,000,000 | 225,000,000 | 53,000,000 | 12,376,000,000 | 1,521,000,000 | 6,694,000,000 |
| Dec 2025 | 1,058,000,000 | 977,000,000 | 243,000,000 | 31,000,000 | 12,873,000,000 | 1,715,000,000 | 7,026,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$875,000,000
Investing CF
$-5,588,000,000
Financing CF
$4,826,000,000
CapEx
$-32,000,000
Dividends Paid
—
Buybacks
$-96,000,000
EPS Diluted TTM
$16.67
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$4,801,000,000
Inventory
$30,000,000
Receivables
$1,298,000,000
ST Investments
$0
EBIT TTM
$1,155,000,000
Pretax Income TTM
$778,000,000
Interest Exp TTM
$377,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,131,000,064
EBITDA
$1,376,999,936
Free Cash Flow
$870,625,024
Enterprise Value
$23,419,727,872
Total Cash
$1,510,000,000
Total Debt
$5,272,999,936
Shares Out
61,490,254
Trailing EPS
$12.64
Book Value
$99.78
ROE
14.0%
ROA
8.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,720,000,000 | 1,250,000,000 | 963,000,000 | 12,873,000,000 | 7,026,000,000 | 5,847,000,000 | 1,186,000,000 |
| Dec 2024 | 3,121,000,000 | 1,015,000,000 | 1,133,000,000 | 6,414,000,000 | 1,277,000,000 | 5,137,000,000 | 1,126,000,000 |
| Dec 2023 | 2,390,000,000 | 772,000,000 | 631,000,000 | 5,232,000,000 | 545,000,000 | 4,687,000,000 | 1,071,000,000 |
| Dec 2022 | 2,087,681,170 | 901,999,165 | 784,697,534 | 4,334,978,914 | 408,324,818 | 3,926,654,097 | 563,047,827 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$13.82
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2026-11-18 19:40 · Yahoo
Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
2026-11-17 23:47 · Yahoo
Genmab (CPSE:GMAB) Stock Could Be 47% Undervalued As Epcoritamab Approvals Expand
2026-11-13 13:13 · Yahoo
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2026-11-12 19:09 · Yahoo
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2026-11-10 20:32 · Yahoo
Is Genmab (CPSE:GMAB) Fully Priced After Holding 2026 Guidance Steady?
2026-11-08 13:13 · Yahoo
What Is Genmab (CPSE:GMAB) Signaling With New Cancer Trial Data?
2026-11-08 12:13 · Yahoo
Genmab (GMAB) Q3 2026 Earnings Call Transcript
2026-11-06 16:16 · Yahoo
Moody’s lifts Genmab outlook to positive on pipeline progress, debt reduction
2026-11-06 16:02 · Yahoo
Genmab AS (GMAB) (Q3 2026) Earnings Call Highlights: Revenue Jumps 22% as Epkinly and Pipeline ...
2026-11-06 07:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.